MARKET WIRETradingView • 1d ago
Lite Strategy, Inc. Estimates – NASDAQ:LITSTradingView report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
Why LITS Stock dropped -13.60% Today — RQD Quant Desk Flash
$0.97 -13.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.94
Lite Strategy Inc. (LITS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $34.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LITS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LITS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Lite Strategy Inc. (NASDAQ: LITS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.97 (-13.60% 1D, market cap $34.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LITS ranks #414 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LITS compare to NNVC and ALDX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LITS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, NNVC (NanoViricides Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $34.0M) and ALDX (Aldeyra Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $33.8M). Among the 5-stock peer group, LITS leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LITS?
▼
Per LITS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001262104), Lite Strategy Inc. generated $48.9M in revenue (-25.2% YoY), -$15.9M in net income, and -$20.8M in free cash flow against $82.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.94 (-2.64%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LITS)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY LITS SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)
Altman Z-Score 11.68 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)
FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 44.6 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.21-1.7% Next Q
51
Q2 (-2Q)Grade D$1.19-2.5% Next Q
48
Q3 (-1Q)Grade D$1.16-16.4% Next Q
46
CurrentGrade D-$0.97-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LITS Turnaround Squeeze
While LITS currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.18) and Max Pain ($1.02) forces dealer call-delta covering toward $2.37.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LITS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LITS Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LITS Stock dropped -13.60% Today — RQD Quant Desk Flash
Lite Strategy Inc. (LITS) dropped -13.60% to $0.97, trading at 18% of its 52-week range ($0.69 – $2.26). Stretched risk/reward at current multiples (-19% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 18% of its 52-week range ($0.69 – $2.26) with RSI-14 at 44.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12% around $0.97 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LITS Headlines & Catalysts
MARKET WIREStock Titan • 1d ago
A 100,000-option director grant at Lite Strategy (LITS) carries a $1.19 exercise price.Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A director receives 100,000 options with a $1.19 exercise price at Lite Strategy (LITS).Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHad-hoc-news.de • 1d ago
Lite Strategy stock falls 4.88% in US sessionad-hoc-news.de report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
600,000 options awarded to Lite Strategy (LITS) CEO Justin J. File carry a $1.19 exercise price.Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
An annual grant gives Lite Strategy (LITS) director James P. Flynn 100,000 options with a $1.19 exercise price.Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 2d ago
LITS Q4 2024 Earnings: Loss Per Share Nearly Double Consensus Despite 4.2% Stock Gain - Strong Earnings Momentumhttps://www.dars.gov.et/ report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
A 100,000-option annual grant at Lite Strategy (LITS) gives director Joshua Riezman 25% immediate vesting.Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 17d ago
Litecoin Just Turned 15. Has It Kept Up With Bitcoin?Fifteen years after launching as Bitcoin's faster, cheaper sibling, Litecoin faces a hard question about whether it has grown into its own or simply fallen behind. The 2027 halving looms as a potential turning point, but
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LITS)
- ✓Walkthrough of LITS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LITS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.91%▼ SUPPORT BREAKDOWN
2026-11-03O $1.17H $1.17L $0.97C $0.97VOL 270.5K
RES: $1.76SUP: $1.04SMA50: $1.18SMA200: $1.09
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LITS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -25.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on LITS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LITS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LITS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LITS)
Health Care Rank #414 of 1015
⚔️ NNVC vs LITS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LITS vs. NNVC, ALDX, EDSA, GRDX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Lite Strategy Inc. (LITS) ranks #414 by composite RQD confidence (43/100, grade D-) and #784 by equity capitalization ($34.1M). Within this direct 5-issuer industry benchmark cohort, LITS leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. LITS currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LITS
ACTIVE
Lite Strategy Inc. | D- | 43/100 | — | — | -18.9% | -13.60% | $34.1M | Benchmark Subject |
| NNVC NanoViricides Inc. | D- | 37/100 | — | — | -35.0% | +1.50% | $34.0M | /nnvc-vs-lits → |
| ALDX Aldeyra Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | +4.09% | $33.8M | /aldx-vs-lits → |
| EDSA Edesa Biotech Inc. | E | 29/100 | — | — | -35.0% | -5.06% | $34.7M | /edsa-vs-lits → |
| GRDX GridAI Technologies Corp. | D- | 39/100 | — | -30.0% | -20.0% | -3.43% | $35.4M | /grdx-vs-lits → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001262104 ↗In its most recent audited fiscal period (FY2025, filed 2025-06-30), Lite Strategy Inc. (LITS) reported GAAP revenue of $48.9M (-25.2% vs. FY2024 revenue of $65.3M , and +0.1% cumulative change since FY2023) , GAAP net income of -$15.9M, operating cash flow of -$20.8M, and free cash flow of -$20.8M (+58.7% YoY). On the balance sheet, LITS closed FY2025 with $82.9M in total assets against $0 in total debt (Altman Z-Score: 11.68, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $48.9M | -$15.9M | -$20.8M | -$20.8M | $82.9M | — |
| FY2024 (FY) | 2024-06-30 | $65.3M | $18.0M | -$50.5M | -$50.5M | $24.4M | — |
| FY2023 (FY) | 2023-06-30 | $48.8M | -$32.0M | -$52.5M | -$52.5M | — | — |
3. LITS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LITS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Lite Strategy Inc. (NASDAQ: LITS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.97 (-13.60% 1D, market cap $34.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LITS ranks #414 in composite RQD confidence.
How does LITS compare to NNVC and ALDX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LITS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, NNVC (NanoViricides Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $34.0M) and ALDX (Aldeyra Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $33.8M). Among the 5-stock peer group, LITS leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LITS?
Per LITS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001262104), Lite Strategy Inc. generated $48.9M in revenue (-25.2% YoY), -$15.9M in net income, and -$20.8M in free cash flow against $82.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LITS trading relative to its 50-day, 200-day, and 52-week technical levels?
LITS last traded at $0.97 (-13.60% on volume of 729,818 shares), positioning the stock -17.80% below its 50-day simple moving average ($1.18) and -11.01% below its 200-day simple moving average ($1.09). Across its 52-week range of $0.69 to $2.26, LITS sits at the 17.8% percentile with a 14-day RSI of 44.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.00 to $1.09).
ROARABLE RATING BRIEF • RQD 43/100 (D-)
✓ SEC XBRL & RQD VERIFIED
LITS — Lite Strategy Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30
1. Roarable Rating Brief: What This Means to a Prospective Investor
Lite Strategy Inc. (LITS) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.97 (-13.60% 1D, market capitalization $34.1M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -18.9%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of 11.68, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
. (LITS) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $65.3M for FY 2024 and — for FY 2025, indicating that reported revenue did not persist into the most recent fiscal year. — for how the company monetizes its activities.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Lite Strategy Inc. (LITS) reported $48.9M in annual revenue (up from $65.3M in FY2024, -25.2% YoY) and -$15.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($48.8M revenue, -$32.0M net income) through FY2025, LITS scaled operating cash flow to -$20.8M and free cash flow to -$20.8M, backed by $82.9M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.69 – $2.26 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
A prospective investor should note that the option grants at $1.19 sit close to the current $1.
- Key Question #1: Can LITS sustain or expand its — operating margin and -18.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $48.9M and free cash flow of -$20.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is LITS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
LITS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Lite Strategy Inc. (LITS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Lite Strategy, Inc. Estimates – NASDAQ:LITS TradingView report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A 100,000-option director grant at Lite Strategy (LITS) carries a $1.19 exercise price. Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A director receives 100,000 options with a $1.19 exercise price at Lite Strategy (LITS). Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH ad-hoc-news.de • 1d ago
Lite Strategy stock falls 4.88% in US session ad-hoc-news.de report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
600,000 options awarded to Lite Strategy (LITS) CEO Justin J. File carry a $1.19 exercise price. Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
An annual grant gives Lite Strategy (LITS) director James P. Flynn 100,000 options with a $1.19 exercise price. Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 2d ago
LITS Q4 2024 Earnings: Loss Per Share Nearly Double Consensus Despite 4.2% Stock Gain - Strong Earnings Momentum https://www.dars.gov.et/ report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
A 100,000-option annual grant at Lite Strategy (LITS) gives director Joshua Riezman 25% immediate vesting. Stock Titan report covering Lite Strategy Inc. (LITS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LITS Bull vs. Bear Conversation Board — What's Your Call at $0.97?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LITS 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $1.38 (+23.2%)
📌 Pinned Debate Altman Z-Score of 11.68 indicates a balance sheet that scores strongly on the forensic pillar despite weak operations.
The street is overcomplicating Lite Strategy Inc. (LITS). Altman Z-Score of 11.68 indicates a balance sheet that scores strongly on the forensic pillar despite weak operations.. With an RQD score of 43/100 (D-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.21.
EarningsSniper 🐂 BULL
Both sides have a point here — LITS's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $0.87 (-22.3%)
Spot @ $1.12 ROIC of -18.9%, zero reported FY 2025 revenue, and a Piotroski F-Score of 1/9 point to a deteriorating cash engine.
I respect the product at Lite Strategy Inc., but the stock at $1.12 is a different story. ROIC of -18.9%, zero reported FY 2025 revenue, and a Piotroski F-Score of 1/9 point to a deteriorating cash engine.. FCF yield is 0.0% and RQD sits at 43/100 (D-) — why pay up here when you can wait for next quarter's numbers?